CCP
GSK icon

Cane Capital Partners’s GSK GSK Stock Holding History

Cane Capital Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$478K Buy
9,120
+1,330
+17% +$70.3K 0.19% 90
2026
Q1 		$430K Sell
7,790
-600
-7% -$32.5K 0.19% 79
2025
Q4 		$411K Buy
+8,390
New +$391K 0.16% 102

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Cane Capital Partners's GSK Position: Q2 2026 in Review

Cane Capital Partners increased its GSK (GSK) stake by 17% in Q2 2026, buying an estimated $70.3K and bringing the position to 9,120 shares worth $478K. The position accounts for 0.19% of the portfolio, ranked #90.

Cane Capital Partners first reported a position in GSK in Q4 2025 and has held it in 3 quarters since. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Cane Capital Partners held 9,120 shares of GSK worth $478K as of Q2 2026.
  • Cane Capital Partners bought 1,330 GSK shares in Q2 2026, an estimated $70.3K.
  • GSK made up 0.19% of Cane Capital Partners's portfolio in Q2 2026, its #90 holding.
  • Cane Capital Partners first reported a position in GSK in Q4 2025 and has held it in 3 quarters since.
  • 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Cane Capital Partners's 13F filing for Q2 2026, filed 5 Aug 2026.